EMERALD-Y90: A phase 2 study to evaluate transarterial radioembolization (TARE) followed by durvalumab (D) and bevacizumab (B) for the treatment of participants (pts) with unresectable hepatocellular carcinoma (uHCC) eligible for embolization.
Year: 2025
Type: article
Source: Journal of Clinical Oncology
Authors: Riad Salem, Anne M. Noonan, Benjamin Spieler, Sarah B. White, Laura Kulik, Dex L. Underwood, Eric Heilbron, Binh Nguyen, Graham Wetherill, Renuka Iyer
Institutions: The Ohio State University Wexner Medical Center, The Ohio State University, University of Miami, Sylvester Comprehensive Cancer Center, Medical College of Wisconsin, Northwestern University, AstraZeneca (United States), AstraZeneca (United Kingdom), Roswell Park Comprehensive Cancer Center
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410814355